Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis

Dermatology

Volumn 219, Issue 3, 2009, Pages 239-249

  Reich, Kristian ^a   Segaert, Siegfried ^b   Van De Kerkhof, Peter ^c   Durian, Cis ^d   Boussuge, Marie Pierre ^e   Paolozzi, Laurence ^e   Wajdula, Joseph ^f   Boggs, Robert ^f  

^a Dermatologikum   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Wyeth Research   (Netherlands)

^e Clinical Research and Development   (France)

^f PFIZER INC   (United States)

Author keywords

Dermatology life quality index; Etanercept; EuroQoL 5D; Psoriasis; Quality of life; Randomized controlled trial

Indexed keywords

ETANERCEPT; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EUROPEAN QUALITY OF LIFE 5D; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350336843     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000237871     Document Type: Article

References (46)

1. National Psoriasis Foundation: Statistics about psoriasis. http://www.psoriasis.org/ about/stats (accessed September 5, 2008).
2. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life; results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
3. Finlay AY, Coles EC: The effects of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-244.
4. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
5. Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
6. Reich K, Griffiths CEM: The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 2008; 300: 537-544.
7. EuroQOL Group: EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
8. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley A, Jahreis A, Zitnik R, Cella D, Krishnan R: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
9. Cella D (ed): Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measure system, version 4.1. Evanston, Center on Outcomes, Research and Education, 2004. http://www.facit.org (accessed April 17, 2008).
10. Kupper TS: Immunologic targets in psoriasis. N Engl J Med 2003; 349: 1987-1990.
11. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R: A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632. (Pubitemid 37523083)
12. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group: Etanercept as monotherapy in subjects with psoriasis. N Engl J Med 2003; 349: 2014-2022.
13. Papp KA, Trying S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group: A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
14. Van de Kerkhof P, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J: Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-tosevere plaque psoriasis. Br J Dermatol 2008; 159: 1177-1185.
15. European Medicines Agency, Committee for Medicinal Products for Human Use: Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. http://www.emea.europa.eu/pdfs/human/ ewp/245402en.pdf (accessed September 12, 2008).
16. Badia X, Mascaro JM, Lozano R: Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. Br J Dermatol 1999; 141: 698-702.
17. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA: Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53.
18. Lewis V, Finlay AY: Ten years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169-180.
19. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA: The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
20. Finlay AY: Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867.
21. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY: Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? Br J Dermatol 2004; 151(suppl 68):45.
22. Kind P: The EuroQol instrument: an index of health-related quality of life; in Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials, ed 2. Philadelphia, Lippincott-Raven, 1996, pp 191-201.
23. Dolan P: Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108.
24. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE: Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002; 24: 547-561.
25. Johnson JA, Coons SJ: Comparison of the EQ-5D and SF-12 in an adult US sample. Qual Life Res 1998; 7: 155-166.
26. Kind P, Hardman G, Macran S: UK population norms for EQ-5D (Measurement and Valuation of Health National Survey). Center for Health Economics Discussion Paper Series, November 1999.
27. Lillegraven S, Kvien TK: Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 827-840.
28. Sobocki P, Ekman M, Agren H, Krakau I, Runeson B, Mårtensson B, Jönsson B: Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health 2007; 10: 153-160.
29. Van Stel HF, Buskens E: Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual Life Outcomes 2006; 4: 20.
30. Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR: Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke 2006; 37: 2567-2572.
31. Stahl E, Lindberg A, Jansson SA, Rönmark E, Svensson K, Andersson F, Löfdahl CG, Lundbäck B: Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3: 56.
32. Glasziou P, Alexander J, Beller E, Clarke P, ADVANCE Collaborative Group: Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes 2007; 5: 21.
33. Cella D, Lai JS, Chang CH, Peterman A, Slavin M: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94: 528-538.
34. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K: Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372.
35. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE: Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006; 154: 1161-1168.
36. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A: Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-557.
37. Reich K, Mrowietz U: Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007; 5: 566-574.
38. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD, British Association of Dermatologists: British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.
39. National Institute for Health and Clinical Excellence: Single technology appraisal: adalimumab (Humira®) for the treatment of moderate to severe plaque psoriasis. Specification for manufacture/sponsor submission of evidence, September 27, 2007, p 67.
40. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M, CNTO 1275 Psoriasis Study Group: A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-592. (Pubitemid 46220818)
41. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W: Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-38. (Pubitemid 40144437)
42. Sato R, Milligan G, Molta C, Singh A, Milligan G: Poor quality of life is associated with increased health care resource utilization independent of disease severity in European plaque psoriasis patients. 65th Annu Meet Am Acad Dermatol, Washington, February 2-6, 2007.
43. Schmitt JM, Ford DE: Work limitations and productivity loss are associated with healthrelated quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213: 102-110.
44. Yount S, Sorensen MV, Cella D, Sengupta N, Grober J, Chartash EK: Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 838-846.
45. Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M, Chiou CF, Patel V, Jahreis A: Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007; 157: 1275-1277.
46. de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD: Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808-814.